Institutional Investors Adjusted ImmunityBio Stakes
Major firms filed second-quarter disclosure reports reflecting shifts in their holdings of ImmunityBio shares.
Updated on Oct. 1, 2026 in Stock Picks
Live Poll
Do you typically adjust your personal investment holdings based on reports of institutional buying activity?
Institutional investors modified their positions in ImmunityBio throughout the second quarter of 2026. These disclosures were released as the biotechnology company saw significant stock growth and awaited upcoming regulatory updates.
Why it matters
Investors are closely monitoring ImmunityBio due to the international reach of its immunotherapy drug Anktiva and ongoing interest in founder Patrick Soon-Shiong's initiatives regarding blockchain-based stock trading.
BlackRock currently holds 34.08 million shares valued at $298.4 million, while Vanguard increased its total position to 36.48 million shares. ImmunityBio stock has seen a 378 percent increase year-to-date.
The players
BlackRock
BlackRock is a prominent global investment management firm that oversees significant assets across various market sectors.
Vanguard
Vanguard is a major American investment advisor known for its extensive range of mutual funds and exchange-traded funds.
Patrick Soon-Shiong
Patrick Soon-Shiong is a surgeon and entrepreneur who serves as the founder and leader of ImmunityBio.
ImmunityBio
ImmunityBio is a biotechnology company focused on the development of immunotherapy treatments for cancer and infectious diseases.
The details
Institutional firms varied their strategies significantly during the second quarter, with Two Sigma Investments raising its stake by 153 percent while Susquehanna and Jane Street reduced holdings by 94 percent and 90 percent respectively. These shifts coincide with market anticipation for an FDA decision regarding the expansion of the Anktiva bladder-cancer label.
Timeline
Vanguard held 34.05 million ImmunityBio shares on March 31, 2026.
The second quarter institutional reporting window closed on June 30, 2026.
ImmunityBio shares grew 19 percent in September 2026.
The FDA is expected to decide on a label expansion by January 6, 2027.
Market Dynamics
Investor activity around ImmunityBio underscores the sensitivity of biotechnology stocks to the FDA's drug label expansion review process. This cycle highlights how institutional capital positions itself in anticipation of regulatory milestones that dictate commercial potential.
Retail investors should note that institutional shifts in ownership can indicate varying levels of confidence in pending regulatory outcomes. Shareholders should monitor upcoming FDA announcements as these decisions frequently trigger significant volatility in the share price.
The takeaway
The sharp divergence in institutional holdings suggests that professional investors are balancing short-term volatility with high-stakes regulatory developments. Investors should maintain a long-term perspective when evaluating biotech stocks subject to specific FDA approval timelines.
What happens next
The FDA is scheduled to reach a decision on the expansion of the Anktiva U.S. bladder-cancer label by January 6, 2027.
Further reading
For more analysis on equity trends and market movements, visit the Stock Picks section.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you typically adjust your personal investment holdings based on reports of institutional buying activity?
